Ampreloxetine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ampreloxetine
Accession Number
DB15348
Type
Small Molecule
Groups
Investigational
Description

Ampreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).

Structure
Thumb
Synonyms
Not Available
External IDs
TD-9855
Categories
UNII
19997EZ42I
CAS number
1227056-84-9
Weight
Average: 321.343
Monoisotopic: 321.134048693
Chemical Formula
C18H18F3NO
InChI Key
TZIALEBTHQWNAO-UHFFFAOYSA-N
InChI
InChI=1S/C18H18F3NO/c19-14-9-16(20)18(17(21)10-14)23-11-13-3-1-2-4-15(13)12-5-7-22-8-6-12/h1-4,9-10,12,22H,5-8,11H2
IUPAC Name
4-{2-[(2,4,6-trifluorophenoxy)methyl]phenyl}piperidine
SMILES
FC1=CC(F)=C(OCC2=CC=CC=C2C2CCNCC2)C(F)=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
64853713

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Fibromyalgia1
1CompletedTreatmentDrug Drug Interaction (DDI)1
1RecruitingTreatmentNOH / Symptomatic Neurogenic Orthostatic Hypertension1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Attention Deficit/Hyperactivity Disorder / Attention-Deficit/Hyperactivity Disorder1
2CompletedTreatmentFibromyalgia1
2CompletedTreatmentMultiple System Atrophy (MSA) / Multiple System Atrophy (MSA) With Orthostatic Hypotension / Neurogenic Orthostatic Hypotension / Neurogenic Orthostatic Hypotension (nOH) / Orthostatic Hypotension / Parkinson Disease With Orthostatic Hypotension / Parkinson's Disease (PD) / Progressive autonomic failure / Pure Autonomic Failure (PAF) / Pure Autonomic Failure With Orthostatic Hypotension1
3RecruitingTreatmentSymptomatic Neurogenic Orthostatic Hypotension3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00146 mg/mLALOGPS
logP4.13ALOGPS
logP4.07ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)10.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity83.2 m3·mol-1ChemAxon
Polarizability31.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:18 / Updated on March 01, 2020 22:06

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates